SCHEMBL2098573

SCHEMBL2098573

COC(=O)C(NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 3/20 0.45
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
CTSS P25774 2/20 0.40
CTSK P43235 2/20 0.40
BTK Q06187 1/20 0.40
GAA P10253 1/20 0.39
EPHX1 P07099 1/20 0.39
CA12 O43570 1/20 0.38
CA14 Q9ULX7 1/20 0.38
REN P00797 2/20 0.37
TSHR P16473 1/20 0.36
CACNA1B Q00975 1/20 0.36
MMP1 P03956 1/20 0.35
MMP8 P22894 1/20 0.35
ADAM17 P78536 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2098572 1.00 AAK1 (0.45) AAK1HDAC4HDAC1HDAC6CTSS
SCHEMBL3048373 1.00 AAK1 (0.45) AAK1HDAC4HDAC1HDAC6CTSS
SCHEMBL2100495 0.88 CTSS (0.44) AAK1HDAC4HDAC1HDAC6CTSS
SCHEMBL1372066 0.88 AAK1 (0.48) AAK1HDAC4HDAC1HDAC6CTSS
SCHEMBL1372065 0.88 AAK1 (0.48) AAK1HDAC4HDAC1HDAC6CTSS
SCHEMBL21904477 0.88 AAK1 (0.48) AAK1HDAC4HDAC1HDAC6CTSS
SCHEMBL2098571 0.87 AAK1 (0.45) AAK1HDAC4HDAC1HDAC6CTSS
SCHEMBL3039102 0.87 AAK1 (0.45) AAK1HDAC4HDAC1HDAC6CTSS
SCHEMBL3037261 0.87 AAK1 (0.45) AAK1HDAC4HDAC1HDAC6CTSS
SCHEMBL24103813 0.86 AAK1 (0.49) AAK1HDAC4HDAC1HDAC6CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163693-B2 Urea-containing peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2012-04-24 US disclosed
EP-2190858-A2 UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2010-06-02 EP disclosed
WO-2009042668-A2 UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2009-04-02 WO disclosed
US-20090082261-A1 UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082261-A1 UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, SLC14A1, RPL35 AAK1 3241/4885HDAC4 3410/4885HDAC1 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.